FDPS Urges FDA to Halt Ibogaine Human Trials, Citing Risk of Fatal Heart Problems and Brain Injury

WASHINGTON, D.C. – The Foundation for Drug Policy Solutions (FDPS) today submitted formal comments urging the Food and Drug Administration (FDA) to halt proposed human clinical trials of ibogaine, an experimental psychedelic drug being promoted as a treatment for opioid addiction and post-traumatic stress disorder (PTSD). The organization warned that the FDA’s own findings raise serious concerns about potentially fatal heart complications, neurological damage, and the lack of reliable evidence demonstrating the drug’s effectiveness. 

In comments submitted to the FDA’s public docket, FDPS called on the agency to place any investigational ibogaine trials on clinical hold until sufficient evidence establishes that human participants can be protected from the drug’s risks. 

“Patients struggling with addiction and PTSD deserve treatments backed by science, not dangerous experiments driven by political pressure or promises of miracle cures,” said Dr. Kevin Sabet, President and CEO of the Foundation for Drug Policy Solutions. “When the FDA itself acknowledges the risk of fatal heart complications and potentially serious brain injury, the answer should be to strengthen safety standards, not rush vulnerable patients into clinical trials.” 

The FDPS comments highlight several major concerns and recommendations: 

  • Potentially fatal heart complications: A 2022 hospital study found that half of the 14 participants receiving ibogaine at 10 mg/kg experienced dangerous QTc prolongation above 500 milliseconds. Published fatalities have occurred as late as 76 hours after ingestion.
  • Risk of brain injury: FDA has acknowledged dose-dependent neurological damage in animal studies, while the potential for lasting brain injury in humans remains unresolved.
  • Stronger patient protections: FDPS calls for at least 96 hours of continuous cardiac monitoring, stricter trial-stopping rules, and long-term follow-up, including safeguards against overdose for patients taken off medications used to treat opioid addiction.
  • Independent oversight and transparency: FDPS urges FDA to prevent financial and advocacy conflicts of interest in clinical trials and publicly disclose relevant relationships between senior agency officials and psychedelic drug developers.
  • Federal law and state programs: FDPS calls for ibogaine to remain a Schedule I substance and urges federal authorities to prevent state-authorized facilities from administering the drug outside federally authorized clinical research.

The comments also warn that federal research funding, political directives, and efforts to accelerate psychedelic drug development must not influence FDA safety determinations. 

FDPS emphasized that its position does not oppose legitimate scientific research or the development of new treatments. Rather, the organization argues that the FDA must require adequate preclinical safety evidence before advancing to further stages of review.

Read the full FDPS comments submitted to FDA

Our family of organizations